GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (CHIX:SOBIs) » Definitions » Cyclically Adjusted PS Ratio

Swedish Orphan Biovitrum AB (CHIX:SOBIS) Cyclically Adjusted PS Ratio : 5.69 (As of Jun. 03, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Swedish Orphan Biovitrum AB's current share price is kr293.20. Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was kr51.57. Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio for today is 5.69.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

CHIX:SOBIs' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.89   Med: 7.26   Max: 21.25
Current: 5.7

During the past years, Swedish Orphan Biovitrum AB's highest Cyclically Adjusted PS Ratio was 21.25. The lowest was 4.89. And the median was 7.26.

CHIX:SOBIs's Cyclically Adjusted PS Ratio is ranked worse than
82.11% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs CHIX:SOBIs: 5.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted revenue per share data for the three months ended in Mar. 2025 was kr18.633. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr51.57 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.22 6.53 5.74 6.16 6.34

Swedish Orphan Biovitrum AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.94 6.10 6.82 6.34 5.59

Competitive Comparison of Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio falls into.


;
;

Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=293.20/51.57
=5.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Swedish Orphan Biovitrum AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=18.633/132.8245*132.8245
=18.633

Current CPI (Mar. 2025) = 132.8245.

Swedish Orphan Biovitrum AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.732 99.995 3.629
201509 2.806 100.228 3.719
201512 2.905 100.276 3.848
201603 4.511 100.751 5.947
201606 5.213 101.019 6.854
201609 4.157 101.138 5.459
201612 4.584 102.022 5.968
201703 4.944 102.022 6.437
201706 5.796 102.752 7.492
201709 5.665 103.279 7.286
201712 6.621 103.793 8.473
201803 6.939 103.962 8.865
201806 8.074 104.875 10.226
201809 8.171 105.679 10.270
201812 9.078 105.912 11.385
201903 10.781 105.886 13.524
201906 10.224 106.742 12.722
201909 9.458 107.214 11.717
201912 15.762 107.766 19.427
202003 14.913 106.563 18.588
202006 9.873 107.498 12.199
202009 9.537 107.635 11.769
202012 14.626 108.296 17.939
202103 11.706 108.360 14.349
202106 10.361 108.928 12.634
202109 12.110 110.338 14.578
202112 15.713 112.486 18.554
202203 15.814 114.825 18.293
202206 12.425 118.384 13.941
202209 12.589 122.296 13.673
202212 19.428 126.365 20.421
202303 16.717 127.042 17.478
202306 15.521 129.407 15.931
202309 16.211 130.224 16.535
202312 19.960 131.912 20.098
202403 18.183 132.205 18.268
202406 15.785 132.716 15.798
202409 19.876 132.304 19.954
202412 21.426 132.987 21.400
202503 18.633 132.825 18.633

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Swedish Orphan Biovitrum AB  (CHIX:SOBIs) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines